Abstract: 【Abstract】 Objective To compare the efficacy and safety of clopidogre and dipyridamole for the prevention of autologous great saphenous venous transposition fistula dysfunction. Methods We prospectively recruited patients who received the operation of autologous great saphenous venous transposition fistula. After the surgery, patients were randomly assigned into either clopidogre group (group A) or dipyridamole group (group B). At the 3rd and 6th months after the enrollment, fistula patency, stenosis rate, arterial anastomotic diameter, venous anastomotic diameter, diameters of the arterial/venous graft segments (3cm from arterial/venous anastomotic sites), complications, and adverse events were recorded. Data were analyzed by using SPSS 17.0 software. Results We observed 30 patients, of which 16 were in group A, and 14 were in group B. At the time points of 3rd and 6th months, group A had a higher fistula patency rate and a lower stenosis rate than group B. At the 6th month, fistula patency was statistically significant between the two groups (P=0.024). Arterial and venous anastomotic diameters were slight wider in group A than in group B but without statistical significance (P＞0.05) at the 3rd month, and were significant larger in group A than in group B (P=0.041 and 0.042, respectively) at the 6th month. Diameters of the arterial/venous graft segments were similar between the two groups at 3rd and 6th months. No severe adverse effects were reported in either of the two groups. Conclusions Clopidogre is superior to dipyridamole in the prevention of thrombosis and stenosis in autologous great saphenous venous transposition fistula without notable adverse effects. As an anti-platelet therapy for fistula preservation, clopidogre shows better effects for clinical use.

Key words: Great saphenous vein, Fistula, Dysfunction, Clopidogre, Dipyridamole